MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Contribution of Genetics to Onset of PD with Leg Tremor

    N. Becker, S. Shah, D. Raymond, M. Rawal, V. Katsnelson, K. Leaver, S. Bressman, R. Saunders-Pullman, C. Young, M. Yang (New York, USA)

    Objective: To determine frequency and determinants of resting tremor in the leg as first motor symptom in Parkinson Disease (PD), especially as related to age…
  • 2024 International Congress

    Determining and Leveraging Local Ancestry to Assess Individual-Level Risk: from the Global Parkinson’s Genetics Program

    G. Parkinson'S_genetics_program (gp2) (Bethesda, USA)

    Objective: We develop a scalable pipeline leveraging existing tools to determine local ancestry for all individuals in the Global Parkinson’s Genetics Program (GP2), aiming to…
  • 2024 International Congress

    Understanding diffusion in extracellular space in synucleinopathy

    J. Estaún-Panzano, S. Nandi, Q. Gresil, C. Mazzocco, ML. Arotcarena, L. Cognet, E. Bezard (Bordeaux, France)

    Objective: To understand the extracellular space (ECS) diffusion in synucleinopathy. Background: The pathogenic mechanisms underlying synucleinopathies involve the spread and propagation of α-synuclein aggregates throughout…
  • 2024 International Congress

    Levels of change in interleukin-6 levels according to clinical stages of Parkinson’s disease in patients with and without Covid-19

    R. Juraev, B. Muminov, R. Matmurodov (Tashkent, Uzbekistan)

    Objective: Comparison of serum IL-6 levels in clinical stages Parkinson's disease  patients with and without Сovid-19. Background: Elevated levels of the cytokine IL-6 may indicate…
  • 2024 International Congress

    Age-associated Changes in Microglial Morphology and its Role in Deciphering Susceptibility to Parkinson’s Disease

    S. Choudhury, P. Abhilash, P. Alladi (Bengaluru, India)

    Objective: To delineate the age-associated changes in microglial morphotypes in the substantia nigra pars compacta (SNpc) of C57BL/6J and CD-1 mice and alterations in response…
  • 2024 International Congress

    Neuropeptide Alterations in Parkinson’s Disease: A Meta-Analysis

    MA. Muneer, V. Suresh, S. Aujla, A. Khare, P. Gowda, V. Ghosh, T. Dave (Lahore, Pakistan)

    Objective: To analyze the levels of different neuropeptides in patients with Parkinson’s disease (PD) compared to healthy individuals. Background: Neuropeptides are bioactive molecules that play…
  • 2024 International Congress

    Can Square Wave Jerks Differentiate Progressive Supranuclear Palsy from Parkinson’s Disease? A Scoping Review

    Y. Xu, N. Bellacicco, E. Feinstein (Newark, USA)

    Objective: To review the available literature regarding the presence and properties of square wave jerks (SWJs) in Progressive Supranuclear Palsy (PSP) and Parkinson’s Disease (PD).…
  • 2024 International Congress

    Benefits of Parkinson’s Team Training Are Maintained Long-Term

    K. Lyons, E. Pollard, D. Beran, C. Hunter(†), H. Cianci, E. Book (Kansas City, USA)

    Objective: To determine if the improvements in confidence to provide and coordinate patient care and understanding of individual and other team member roles among interprofessional…
  • 2024 International Congress

    Patient-reported changes from normal in individuals with prodromal and early-motor Parkinson’s disease: a scoping review

    J. Saade, T. Mestre, G. Stebbins, A. van Wyk (Ottawa, Canada)

    Objective: To synthesize published literature about patient-reported symptoms (PRS) or changes from normal in prodromal and early motor stages of Parkinson’s disease (PD) and develop…
  • 2024 International Congress

    Association between use of Furosemide and Risk of Parkinson’s disease

    B. Babar, AM. Tolppanen, S. Hartikainen, M. Tiihonen (Kuopio, Finland)

    Objective: Main objective of study is to check the association between furosemide use and risk of Parkinson's disease (PD) in a Finnish nationwide nested case-control…
  • « Previous Page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley